Skandinaviska Enskilda Banken (SEB)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,300	Closed	-$127K	–	1089
2021 Q3	$127K	Buy	+6,300	New	+$174K	﹤0.01%	951
2020 Q3	–	Sell	-28,000	Closed	-$711K	–	1140
2020 Q2	$711K	Buy	+28,000	New	+$603K	0.01%	770

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s DRNA Position: Q4 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 6,300 shares — an estimated $127K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in DRNA in Q2 2020 and held it in 2 quarters. The position peaked at $711K in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Skandinaviska Enskilda Banken (SEB) reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 6,300 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $127K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
Skandinaviska Enskilda Banken (SEB)'s Dicerna Pharmaceuticals, Inc. position peaked at $711K in Q2 2020.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2021, filed 10 Feb 2022.